The study investigates the long-term administration of alpha-interferon and lamivudine in patients with chronic Hepatitis B, focusing on their efficacy and safety. This research includes a comprehensive analysis of treatment outcomes, side effects, and patient quality of life. Evidence from clinical observations suggests that alpha-interferon combined with lamivudine demonstrates significant antiviral effects, reducing viral load and improving liver function in patients over extended periods. The findings advocate for this combination therapy as a viable option in managing chronic Hepatitis B, balancing its benefits against potential adverse effects.
Jaboli et al. (Mon,) studied this question.